Shared Decision Making in Patient Care: Involving Patients in Treatment Choices

Shared decision making sits at the intersection of medical expertise and personal values — the place where a clinician's knowledge about what can be done meets a patient's knowledge about what matters to them. This page covers the definition, mechanics, common clinical applications, and the important boundaries of where this model applies and where it doesn't. The stakes are real: research consistently shows that patients who participate actively in treatment decisions report higher satisfaction, better adherence to chosen treatments, and in some conditions, measurably better outcomes.

Definition and scope

A physician walks into a room and knows that 3 reasonable treatment paths exist for a patient's early-stage prostate cancer — active surveillance, radiation, and surgery. Each carries different risk profiles and different effects on quality of life. Which one is "right" depends partly on clinical data and partly on whether that particular patient values preserving sexual function, minimizing ongoing anxiety, or avoiding anesthesia. No algorithm settles that.

Shared decision making (SDM) is the formal model for navigating exactly that situation. The Agency for Healthcare Research and Quality (AHRQ) defines it as a process in which clinicians and patients work together to make health decisions, with clinicians providing evidence on options and patients contributing their preferences and values. It is distinct from informed consent, which is a legal threshold — a patient's agreement after disclosure — rather than a collaborative process. For more on how informed consent fits into the broader picture, see the Informed Consent Process page.

The scope of SDM encompasses any clinical situation involving preference-sensitive care: decisions where the medically appropriate choice genuinely depends on individual values rather than a single clearly superior clinical path. The model applies across primary care, specialty medicine, chronic disease management, end-of-life planning, and behavioral health settings.

How it works

SDM is not a single conversation — it's a structured exchange that AHRQ and the National Academy of Medicine describe through three core phases:

1. Choice awareness — The clinician makes clear that a real choice exists and that the patient's input matters. This sounds obvious but is routinely skipped; studies cited by AHRQ have found that clinicians inform patients of alternatives in fewer than half of clinical encounters where alternatives exist.
2. Option review — Both parties examine the available options using evidence-based information about benefits, risks, and likely outcomes. Decision aids — structured written or digital tools — are commonly used here to present probabilities in accessible formats.
3. Preference integration and decision — The patient's values are explicitly incorporated, questions are answered, and a decision is reached collaboratively. The clinician does not simply defer to the patient; expertise remains active throughout.

Decision aids are a key mechanism. The Cochrane Collaboration has conducted systematic reviews of over 100 decision aid trials, finding that patients who used decision aids were more knowledgeable about their options, had more accurate risk perceptions, and were less likely to remain undecided after consultations than patients who received standard care.

SDM connects closely to the broader patient-centered care model, which frames clinical care around individual goals rather than disease categories alone.

Common scenarios

SDM appears across a wide range of clinical settings. The following are the most frequently documented applications:

• Cancer treatment selection — Early-stage breast and prostate cancers, where multiple treatment modalities carry comparable survival data but different side effect profiles, are among the most studied SDM contexts.
• Cardiovascular decisions — Choices between medication management and procedural intervention for stable coronary artery disease involve meaningful trade-offs that depend heavily on patient tolerance for risk and recovery.
• Chronic disease management — Patients managing conditions like type 2 diabetes or rheumatoid arthritis face long-term medication regimens with real differences in side effects, administration routes, and lifestyle impact. Chronic disease management services increasingly incorporate SDM frameworks.
• Mental health treatment — Decisions about antidepressant selection, psychotherapy modality, or medication-assisted treatment for substance use disorders involve both clinical evidence and individual experience of side effects and stigma.
• Advance care planning — Discussions about goals of care, resuscitation preferences, and end-of-life treatment align directly with SDM principles. See the Advance Directives and Patient Wishes page for more detail.

The National Patient Services Authority reference hub covers many of these clinical areas with condition-specific guidance.

Decision boundaries

SDM is not universal, and misapplying it can cause harm. Three distinctions matter here:

Preference-sensitive vs. effective care. SDM applies to preference-sensitive decisions. For conditions with a single clearly superior clinical pathway — a burst appendix, a ST-elevation myocardial infarction requiring immediate intervention — delay for collaborative deliberation is medically dangerous. Effective care means one answer is correct; the model doesn't change that.

Patient autonomy vs. abandonment. SDM requires clinician engagement. A physician who presents options without recommendations and defers entirely to the patient is not practicing SDM — a concept sometimes called "informed non-dissent." The Institute of Medicine, now the National Academy of Medicine, has noted that patients frequently want a recommendation alongside information, not instead of it.

Capacity considerations. SDM assumes decision-making capacity. When patients lack capacity — due to acute cognitive impairment, altered consciousness, or severe psychiatric crisis — surrogate decision making governed by advance directives or legal proxies replaces the SDM model. The transition between those two frameworks is not always clean, and clinicians are expected to assess capacity formally when doubt exists.

Understanding where SDM ends and other frameworks begin is as important as understanding where it begins. Patient rights within those frameworks are addressed on the Patient Rights and Responsibilities page.

References

• Agency for Healthcare Research and Quality (AHRQ) — Shared Decision Making
• Cochrane Review: Decision aids for people facing health treatment or screening decisions
• National Academy of Medicine (formerly Institute of Medicine)
• National Learning Consortium — Shared Decision Making Fact Sheet (HealthIT.gov)